Insilico Medicine develops highly selective FGFR2/3 dual inhibitor for cancer treatment
Fibroblast growth factor receptors (FGFRs) are critical drivers of oncogenesis in various solid tumors, including urothelial carcinoma, hepatocellular carcinoma, ovarian cancer and lung adenocarcinoma. However, developing…
Read More...
Read More...